Quintiles Completes Acquisition of Novella Clinical
Quintiles today announced that it has completed the previously announced  acquisition of Novella Clinical  (Novella), a full-service clinical research organization (CRO) focused primarily on emerging oncology customers as well as those in the medical device and diagnostics sectors.
“We are extremely pleased to have completed the acquisition of Novella and look forward to working together to increase our collective opportunities with emerging oncology and medical device companies,” said Paula Brown Stafford, president, Clinical Development at Quintiles. “With the transaction now officially closed, we will focus our efforts on leveraging Quintiles’ global resources and capabilities with the expertise and personal attention of Novella to continue to deliver the high-quality services customers have come to expect from both companies.”
Now known as “Novella Clinical, a Quintiles company,” Novella will operate as a unit within Quintiles, retaining its existing leadership team as well as its specialized customer focus.
Quintiles (NYSE:Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 27,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-50 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com .
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect, among other things, Quintiles’ current expectations and anticipated results of operations, all of which are subject to known and unknown risks, uncertainties and other factors that may cause Quintiles’ actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. Therefore, any statements contained herein that are not statements of historical fact may be forward-looking statements and should be evaluated as such. Without limiting the foregoing, the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “should,” “targets,” “will” and the negative thereof and similar words and expressions are intended to identify forward-looking statements.
These statements are subject to risks, uncertainties and assumptions, including our ability to complete, integrate and achieve our intended objectives with respect to the proposed acquisition of Novella Clinical and those described under the section entitled "Risk Factors" in Quintiles’ prospectus dated May 8, 2013, filed with the SEC pursuant to Rule 424(b) of the Securities Act on May 9, 2013, as such factors may be updated from time to time in Quintiles’ periodic filings with the SEC, which are accessible on the SEC's website at www.sec.gov . These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in Quintiles’ filings with the SEC. Unless legally required, Quintiles assumes no obligation to update any such forward-looking information to reflect actual results or changes in the factors affecting such forward-looking information.
Click here  to subscribe to Mobile Alerts for Quintiles.